Cargando…
Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes
Irbesartan has shown significant therapeutic effects in hypertensive patients with non-alcoholic fatty liver disease (NAFLD). To determine the underlying mechanisms of its action, we established an in vitro model of NAFLD by treating human and mouse hepatocytes with free fatty acids (FFAs) and angio...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548903/ https://www.ncbi.nlm.nih.gov/pubmed/31191364 http://dx.doi.org/10.3389/fphys.2019.00681 |
_version_ | 1783423895586471936 |
---|---|
author | He, Juan Ding, Jian Lai, Qiuhua Wang, Xinke Li, Aimin Liu, Side |
author_facet | He, Juan Ding, Jian Lai, Qiuhua Wang, Xinke Li, Aimin Liu, Side |
author_sort | He, Juan |
collection | PubMed |
description | Irbesartan has shown significant therapeutic effects in hypertensive patients with non-alcoholic fatty liver disease (NAFLD). To determine the underlying mechanisms of its action, we established an in vitro model of NAFLD by treating human and mouse hepatocytes with free fatty acids (FFAs) and angiotensin (Ang) II. Irbesartan significantly reversed AngII/FFA-induced lipid deposition and mitochondrial dysfunction by restoring ATP production and the mitochondrial membrane potential (MMP), and decreasing the levels of reactive oxygen species (ROS) and inflammatory markers. In addition, irbesartan also increased the autophagy flux, in terms of increased numbers of autolysosomes and autophagosomes, and the upregulation and mitochondrial localization of the autophagic proteins Atg5 and LC3BII/I. Activation of protein kinase C (PKC) and inhibition of the autophagic flux exacerbated mitochondrial dysfunction in the steatotic hepatocytes. Furthermore, AngII upregulated PKC which inhibited AMPK phosphorylation via direct interaction with the AngII receptor AT1-R. Irbesartan inhibited PKC and activated AMPK and its downstream effector ULK1, thereby inducing autophagy, decreasing lipid deposition, and restoring mitochondrial function. Taken together, irbesartan triggers autophagy via the PKC/AMPK/ULK1 axis to ameliorate the pathological changes in the steatotic hepatocytes. |
format | Online Article Text |
id | pubmed-6548903 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-65489032019-06-12 Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes He, Juan Ding, Jian Lai, Qiuhua Wang, Xinke Li, Aimin Liu, Side Front Physiol Physiology Irbesartan has shown significant therapeutic effects in hypertensive patients with non-alcoholic fatty liver disease (NAFLD). To determine the underlying mechanisms of its action, we established an in vitro model of NAFLD by treating human and mouse hepatocytes with free fatty acids (FFAs) and angiotensin (Ang) II. Irbesartan significantly reversed AngII/FFA-induced lipid deposition and mitochondrial dysfunction by restoring ATP production and the mitochondrial membrane potential (MMP), and decreasing the levels of reactive oxygen species (ROS) and inflammatory markers. In addition, irbesartan also increased the autophagy flux, in terms of increased numbers of autolysosomes and autophagosomes, and the upregulation and mitochondrial localization of the autophagic proteins Atg5 and LC3BII/I. Activation of protein kinase C (PKC) and inhibition of the autophagic flux exacerbated mitochondrial dysfunction in the steatotic hepatocytes. Furthermore, AngII upregulated PKC which inhibited AMPK phosphorylation via direct interaction with the AngII receptor AT1-R. Irbesartan inhibited PKC and activated AMPK and its downstream effector ULK1, thereby inducing autophagy, decreasing lipid deposition, and restoring mitochondrial function. Taken together, irbesartan triggers autophagy via the PKC/AMPK/ULK1 axis to ameliorate the pathological changes in the steatotic hepatocytes. Frontiers Media S.A. 2019-05-29 /pmc/articles/PMC6548903/ /pubmed/31191364 http://dx.doi.org/10.3389/fphys.2019.00681 Text en Copyright © 2019 He, Ding, Lai, Wang, Li and Liu. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Physiology He, Juan Ding, Jian Lai, Qiuhua Wang, Xinke Li, Aimin Liu, Side Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title_full | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title_fullStr | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title_full_unstemmed | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title_short | Irbesartan Ameliorates Lipid Deposition by Enhancing Autophagy via PKC/AMPK/ULK1 Axis in Free Fatty Acid Induced Hepatocytes |
title_sort | irbesartan ameliorates lipid deposition by enhancing autophagy via pkc/ampk/ulk1 axis in free fatty acid induced hepatocytes |
topic | Physiology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6548903/ https://www.ncbi.nlm.nih.gov/pubmed/31191364 http://dx.doi.org/10.3389/fphys.2019.00681 |
work_keys_str_mv | AT hejuan irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes AT dingjian irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes AT laiqiuhua irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes AT wangxinke irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes AT liaimin irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes AT liuside irbesartanameliorateslipiddepositionbyenhancingautophagyviapkcampkulk1axisinfreefattyacidinducedhepatocytes |